Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early– and Late–Stage Primary Biliary Cirrhosis

Hempfling, Wolfgang, Grunhage, Frank, Dilger, Karin, Reichel, Christoph, Beuers, Ulrich, Sauerbruch, Tilman · 2003 · Hepatology

Abstract

Budesonide has been discussed as a potential treatment option in primary biliary cirrhosis (PBC). Therefore, we studied the pharmacokinetics and pharmacodynamics of budesonide in patients with PBC stage I/II and stage IV. Twelve patients with early PBC stage I/II and 7 patients with PBC stage IV under continuous treatment with ursodeoxycholic acid (UDCA) were enrolled in an exploratory trial. Each patient received oral budesonide for 3 weeks at weekly increasing dosages of 3 mg once to thrice per day. Budesonide and cortisol plasma levels, urinary cortisol excretion, serum liver tests, and immunoglobulins were determined on days 1, 7, and 21 of the study. Patients with PBC stage IV showed significantly higher peak plasma concentrations (4.9 ± 3.5 vs. 1.5 ± 0.4 ng/mL; P < .05) and areas under the plasma concentration–time curves (AUC) (23.2 ± 16.8 vs. 5.1 ± 1.4 hours · ng/mL, P < .01, total AUC extrapolated to infinity [AUC 0–∞]) after a single dose of 3 mg budesonide when compared with patients with PBC stage I/II. Equally, AUC of budesonide were significantly increased under a multiple dose regimen on day 21 (14.0 ± 11.6 vs. 5.0 ± 1.9 hours · ng/mL, P < .01, AUC at steady state from dosing time to 8 hours [AUC ss,0–8 h]). Higher levels of budesonide were related to a significant decrease in plasma cortisol and reduction of urinary cortisol excretion in patients with stage IV disease. Two patients with stage IV disease developed portal vein thrombosis (PVT). In conclusion, administration of budesonide leads to markedly elevated plasma levels in cirrhotic patients with PBC associated with serious adverse drug reactions. Thus, further evaluation of combined treatment with UDCA may be considered in early–stage PBC but not in cirrhotic patients with PBC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/jhep.2003.50266

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 28

  1. Heathcote, 2000, Hepatology, 31, 1005, 10.1053/he.2000.5984 · DOI · Paper page
  2. Neuberger, 1997, Lancet, 350, 875, 10.1016/S0140-6736(97)05419-6 · DOI · Paper page
  3. Heathcote, 2000, Can J Gastroenterol, 14, 43, 10.1155/2000/989486 · DOI
  4. Leuschner, 2000, Gut, 46, 121, 10.1136/gut.46.1.121 · DOI
  5. Pasha, 1996, Med Clin North Am, 80, 995, 10.1016/S0025-7125(05)70477-6 · DOI
  6. Mitchison, 1989, Hepatology, 10, 420, 10.1002/hep.1840100405 · DOI
  7. Bar-Meir, 1998, Gastroenterology, 115, 835, 10.1016/S0016-5085(98)70254-9 · DOI · Paper page
  8. Greenberg, 1994, N Engl J Med, 331, 836, 10.1056/NEJM199409293311303 · DOI · Paper page
  9. Ryrfeldt, 1982, Eur J Respir Dis Suppl, 122, 86
  10. Jonsson, 1995, Drug Metab Dispos, 23, 137
  11. , , , , . Principles of topical versus systemic corticoid treatment in inflammatory bowel disease. In: , eds. Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy. Boston: Kluwer, 1996:42-60.
  12. Angulo, 2000, Hepatology, 31, 318, 10.1002/hep.510310209 · DOI · Paper page
  13. George, 1995, Hepatology, 21, 120
  14. Rodighiero, 1999, Clin Pharmacokinet, 37, 399, 10.2165/00003088-199937050-00004 · DOI · Paper page
  15. . Clinical Pharmacokinetics. Concepts and Applications. Baltimore: Williams & Wilkins, 1995:117-130.
  16. Steinijans, 1992, Int J Clin Pharmacol Ther Toxicol, 30, s45
  17. , , , , , , et al. Pharmacokinetics and pharmacodynamics of budesonide-ph-modified release capsules. In: , eds. Glucocorticoid Therapy in Chronic Inflammatory Bowel Disease. From Basic Principles to Rational Therapy. Boston: Kluwer, 1996:107-120.
  18. Blendis, 2001, Pharmacol Ther, 89, 221, 10.1016/S0163-7258(01)00124-3 · DOI
  19. Cahill, 2001, Pharmacol Ther, 89, 273, 10.1016/S0163-7258(01)00128-0 · DOI
  20. Pihusch, 2002, J Hepatol, 37, 548, 10.1016/S0168-8278(02)00239-8 · DOI
  21. McLean, 1991, Clin Pharmacokinet, 21, 42, 10.2165/00003088-199121010-00004 · doi:10.2165/00003088-199121010-00004
  22. Morgan, 1995, Clin Pharmacokinet, 29, 370, 10.2165/00003088-199529050-00005 · DOI · Paper page
  23. Doherty, 2002, Clin Pharmacokinet, 41, 235, 10.2165/00003088-200241040-00001 · DOI · Paper page
  24. Schwab, 2001, Clin Pharmacokinet, 40, 723, 10.2165/00003088-200140100-00003 · DOI
  25. Hanauer, 1998, Gastroenterology, 115, 525, 10.1016/S0016-5085(98)70131-3 · DOI · Paper page
  26. Baker, 1999, Pediatrics, 103, 414, 10.1542/peds.103.2.414 · DOI · Paper page
  27. Nana, 1998, J Asthma, 35, 647, 10.3109/02770909809048967 · DOI
  28. Angulo, 2000, Am J Gastroenterol, 95, 2333, 10.1111/j.1572-0241.2000.02323.x · DOI

Cited by

See all 165

Metadata

Authors
Hempfling, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U., & Sauerbruch, T.
Venue
Hepatology
Published
2003-07
Volume
38
Issue
1
Pages
196-202
ISSN
0270-9139 (ISSN-L)
OpenAlex
W1999672624
Cited by
165
References
4
FWCI
3.47
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 4445 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early– and Late–Stage Primary Biliary Cirrhosis. https://app.cochat.ai/papers/10.1053/jhep.2003.50266
The paper
Hempfling, W., Grunhage, F., Dilger, K., Reichel, C., Beuers, U., & Sauerbruch, T. (2003). Pharmacokinetics and Pharmacodynamic Action of Budesonide in Early– and Late–Stage Primary Biliary Cirrhosis. Hepatology. https://doi.org/10.1053/jhep.2003.50266

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.